Recommended instructions for the correct usage, dosage and taking time of Mecobalamin tablets

Methylcobalamin injection (Rozebalamin) is a new type of drug developed in Japan. Its core indication is amyotrophic lateral sclerosis (ALS, commonly known as amyotrophic lateral sclerosis). According to the existing drug instructions, this product is mainly used to slow down the progression of dysfunction in ALS patients. It is not a conventional drug for general nerve repair or lumbar and cervical spine-related diseases in the traditional sense. Its positioning is significantly different from the methylcobalamin oral preparations commonly used in clinical practice in the past.

From the perspective of its mechanism of action, the drug participates in the methyl transfer reaction and neuroprotection process in nerve cells through high-dose, injection administration, and may have a positive impact on the survival and functional maintenance of motor neurons. Research shows that its use in early or mid-stage ALS patients can help delay the decline in muscle strength and impairment of daily functions, but it cannot reverse the nerve damage that has already occurred. Therefore, it emphasizes the importance of standardizing medication as early as possible.

In terms of usage, this drug is a prescription-grade new drug for injection. The specific dosage, frequency and course of treatment must be strictly followed by the doctor and instructions. It is usually a long-term, regular treatment plan. Since ALS itself is a progressive neurodegenerative disease, the treatment goal is more to "delay the progression" than to cure it. Patients need to cooperate with functional assessment, respiratory function monitoring and multidisciplinary management during the treatment process.
In terms of drug safety, existing clinical data show that its overall tolerability is acceptable, but discomfort at the injection site, mild allergic reactions, or fluctuations in laboratory indicators may still occur. Since this drug is a new drug developed in Japan, the user population is relatively limited. Patients should be followed up regularly during treatment, closely observe the efficacy and adverse reactions, and avoid expanding the indications on their own to ensure drug safety and maximize clinical benefits.
Reference: https://www.drugs.com/